Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01591421
Recruitment Status : Completed
First Posted : May 4, 2012
Last Update Posted : April 7, 2020
Information provided by (Responsible Party):
Canadian Cancer Trials Group

Tracking Information
First Submitted Date  ICMJE May 2, 2012
First Posted Date  ICMJE May 4, 2012
Last Update Posted Date April 7, 2020
Actual Study Start Date  ICMJE May 1, 2012
Actual Primary Completion Date September 30, 2015   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 9, 2012)
Recommended phase II dose of BKM120 (Phase I Component) [ Time Frame: 24 months ]
Determine the safety, tolerability, toxicity profile and dose limiting toxicities of BKM120 and Panitumumab.
Original Primary Outcome Measures  ICMJE
 (submitted: May 3, 2012)
Recommended phase II dose of BKM120 [ Time Frame: 24 months ]
To determine the recommended phase II dose of BKM120 in combination with standard panitumumab therapy in patients with locally advanced or metastatic colorectal cancer (CRC) after failure of at least one prior chemotherapy regimen, and whose RAS mutation status is wild-type.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: May 9, 2012)
  • Anti-tumour activity (Phase II Component) [ Time Frame: 24 months ]
    To assess the anti-tumour activity of BKM120 in combination with panitumumab as evidenced by response rates and early progression rates in patients with K-RAS wild-type metastatic colorectal cancer.
  • Translational Research [ Time Frame: 24 months ]
    To investigate the correlation, if any, between response and molecular biomarkers in archival FFPE tumour.
Original Secondary Outcome Measures  ICMJE
 (submitted: May 3, 2012)
  • Tolerability [ Time Frame: 24 months ]
    Maximum tolerated dose of BKM120 in participants.
  • Anti-tumour activity [ Time Frame: 24 months ]
    To assess the anti-tumour activity of BKM120 in combination with panitumumab as evidenced by response rates and early progression rates in patients with K-RAS wild-type metastatic colorectal cancer.
  • Translational Research [ Time Frame: 24 months ]
    To investigate the correlation, if any, between response and molecular biomarkers in archival FFPE tumour.
  • Toxicity profile [ Time Frame: 24 months ]
    Number and severity of adverse events.
  • Dose limiting toxicities [ Time Frame: 24 months ]
    Adverse events of BKM120 in participants resulting in dose limitations.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer.
Official Title  ICMJE Phase I/II Study of the P13Kinase Inhibitor BKM120 Given in Combination With Panitumumab in Patients With Metastatic or Advanced RAS-Wild Type Colorectal Cancer.
Brief Summary

For the first phase of this study (phase I), the purpose will be to find the dose of a new drug, BKM120, that can safely be given in combination with standard dose panitumumab.

For the second phase of this study (phase II), the purpose is to find out what effects the combination of BKM120 and panitumumab, in doses found to be safe in the first part of the study, has on patients and their colorectal cancer.

Detailed Description This is done by starting with doses of BKM120 at lower than the usual dose. Patients are given BKM120 and panitumumab and are watched very closely to see what side effects they have and to make sure the side effects are not severe. If the side effects are not severe, then more patients are asked to join the study and are given higher doses of BKM120. If severe toxicity is seen, doses of BKM120 and/or panitumumab doses may be lowered in subsequent patients. Patients joining the study later on will normally get higher doses of BKM120 than patients who join earlier. This will continue until a dose is found that causes severe but temporary side effects. Doses higher than that will not be given.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Metastatic Colorectal Cancer
Intervention  ICMJE
  • Drug: BKM120
    PO; Once daily starting day 1 cycle 1, or 5 out of 7 days every week.
  • Drug: Panitumumab
    IV; Every two weeks starting day 1 cycle 1 (i.e. day 1 and 15 each 28 day cycle)
Study Arms  ICMJE Experimental: BKM120 and Panitumumab
BKM120 will be given either daily starting day 1 cycle 1or 5 out of 7 days every week, depending on when patient is enrolled on the study, in combination with panitumumab given intravenously every two weeks starting day 1 cycle 1.
  • Drug: BKM120
  • Drug: Panitumumab
Publications * Goodwin R, Jonker D, Chen E, Kennecke H, Cabanero M, Tsao MS, Vickers M, Bohemier C, Lim H, Ritter H, Tu D, Seymour L. A phase Ib study of a PI3Kinase inhibitor BKM120 in combination with panitumumab in patients with KRAS wild-type advanced colorectal cancer. Invest New Drugs. 2020 Aug;38(4):1077-1084. doi: 10.1007/s10637-019-00814-3. Epub 2019 Sep 10.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 14, 2015)
Original Estimated Enrollment  ICMJE
 (submitted: May 3, 2012)
Actual Study Completion Date  ICMJE November 12, 2019
Actual Primary Completion Date September 30, 2015   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Histologic proof of a primary colorectal cancer which is recurrent or metastatic.
  • Tumour must be confirmed to be K-Ras wild type (i.e. no K-Ras mutation found) by means of mutation analysis performed on representative samples of diagnostic tumour tissue by the standard regional or provincial laboratory and be eligible to receive standard panitumumab treatment as per local guidelines (i.e. must have failed, or have been unable to receive prior irinotecan, oxaliplatin and thymidylate synthase inhibitor therapy). Note: Archival tumour samples are acceptable for K-Ras mutation analysis.
  • In the phase I portion of the trial, patients may have measurable OR non-measurable disease. Patients whose only evidence of disease progression is tumour marker elevation are not eligible.
  • In the phase II portion of the trial, all patients must have measurable disease as defined by RECIST 1.1.

The criteria for defining measurable disease are as follows:

Chest X-ray ≥ 20 mm CT/MRI scan (with slice thickness of < 5 mm) ≥ 10 mm → longest diameter Physical exam (using calipers) ≥ 10 mm Lymph nodes by CT scan ≥ 15 mm → measured in short axis

Patients must have recovered from recent surgery, chemotherapy and/or radiation therapy and significant toxicity must have recovered to ≤ grade 2. At least 4 weeks must have elapsed from major surgery and radiation therapy, unless the radiation is low dose, does not involve mucosa and is non-myelosuppressive. Patient must have recovered (grade 0-1) from all reversible toxicity related to prior chemotherapy and have adequate washout from prior chemotherapy and investigational agents as follows: Washout period is the longest of one of the following:

  1. two weeks
  2. standard cycle length of prior regimen (i.e. 21 days for irinotecan q 3 weeks).
  3. 10 half-lives for investigational drugs.

ECOG performance status of 0, 1 or 2.

  • Laboratory Requirements: (must be done within 7 days prior to registration) Hematology: Absolute granulocytes (AGC) ≥ 1.0 x 109/L Platelets ≥ 100 x 109/L Hemoglobin ≥ 90 g/L Chemistry: Serum creatinine ≤ 1.5 x UNL OR Creatinine clearance ≥ 50 ml/min Bilirubin * ≤ UNL AST and ALT ≤ 3.0 x UNL Potassium ≤ UNL Calcium ≤ UNL Magnesium ≥ 0.5 mmol/L (may be achieved with supplementation) Blood glucose (fasting) < 7.8 mmol/L Coagulation: INR ≤ 2 x UNL (* direct, if patient known to have Gilberts)
  • Patient must consent to provision of, and investigator(s) must confirm access to and agree to submit at the request of the NCIC CTG Central Tumour Bank, a representative formalin fixed paraffin block of tumour tissue in order that the correlative marker assays may be conducted. Where local centre regulations prohibit submission of blocks of tumour tissue, the approval of the NCIC CTG must be sought prior to registration of the first patient to allow a predetermined number of slides of representative tumour tissue to be substituted in response to the Central Tumour Bank request. Failure to submit any tissue samples on request will result in the patient being considered ineligible. Where no previously resected or biopsied tumour tissue exists, on the approval of the NCIC CTG, the patient may still be considered eligible for the study.
  • Age ≥ 18 years. (Note that the lower age limit at each centre will be determined by that centre's policy regarding the age at which an individual may sign their own consent.)
  • Women of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to registration. Patients of reproductive potential must agree to use highly effective contraception as follows:
  • Female study subjects: during study and for 6 months after final dose of study therapy
  • Male study subjects: during study and until 16 weeks after final dose of study therapy.
  • Female partner of male study subject: during study and until 16 weeks after final dose of study therapy
  • Patient consent for trial participation must be obtained according to local Institutional and/or University Human Experimentation Committee requirements. It will be the responsibility of the local participating investigators to obtain the necessary local clearance, and to indicate in writing to the NCIC CTG Study Coordinator that such clearance has been obtained, before the trial can commence in that centre. Because of differing requirements, standard consent forms for the trial will not be provided but sample forms are provided. A copy of the initial full board Research Ethics Board (REB) approval and approved consent forms must be sent to the central office. The patient must sign the consent forms prior to registration. Please note that the consent forms for this study must contain a statement which gives permission for qualified representatives of the CCTG, monitoring agencies and regulatory authorities to review patient records.
  • Patients must be accessible for treatment and follow-up. Investigators must assure themselves the patients registered on this trial will be available for complete documentation of the treatment, adverse events, and follow-up. Patients enrolled in this trial must be treated and followed at the participating centre. This implies there must be a reasonable geographical limit (for example: 2 hour's driving distance) placed on the patients being considered for this trial.
  • Protocol treatment is to begin within 5 working days of patient registration.

Exclusion Criteria:

  • A history of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for > 5 years.
  • Women who are pregnant or breastfeeding.
  • Any active disease condition which would render the protocol treatment dangerous or impair the ability of the patient to receive protocol therapy (e.g. chronic pancreatitis, active chronic hepatitis, etc.).
  • Any condition (e.g. psychological, geographical, etc.) that does not permit compliance with the protocol.
  • Uncontrolled or significant cardiovascular disease including:

    • Myocardial infarction within 12 months;
    • Uncontrolled angina within 6 months;
    • Clinically significant congestive heart failure;
    • Stroke;
    • TIA or other ischemic event within 12 months;
    • Severe cardiac valve dysfunction
  • Phase I: Patients may not be diabetic
  • Phase II: Patients may be diabetic, but must have controlled diabetes (fasting glucose < 7.8 mmol/L)
  • Patient has any of the following mood disorders:

    • Medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (immediate risk of doing harm to others)
    • ≥ CTCAE grade 3 anxiety
    • score of ≥ 10 in the PHQ-9
    • score of ≥ 15 in the GAD-7 mood scale
    • patient selects a positive response of '1, 2, 3' to question number 9 (suicidal ideation) in the PHQ-9
  • Symptomatic metastases in the central nervous system. Subjects with signs or symptoms suggestive of brain metastasis are not eligible unless brain metastases are ruled out by CT or MRI scans.
  • Patients who have received prior EGFR or PI3 Kinase inhibitor therapy.
  • Receipt of an investigational therapeutic agent within washout period defined in section 5.1.4 of the protocol.
  • Severe restrictive lung disease or radiological pulmonary findings of "interstitial lung disease" on the baseline chest x-ray which, in the opinion of the investigator, represents significant pathology.
  • Patients with impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of BKM120 (e.g. ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).
  • Patients who are unable to swallow capsules.
  • Patients on potent CYP3A Inhibitors/Inducers (must have discontinued > 7 days prior to day 1) or therapeutic doses of warfarin like anticoagulants. Patients may receive low molecular weight heparin if indicated.
  • Patients receiving chronic treatment with steroids or another immunosuppressive agent. Note: Topical applications (e.g. rash), inhaled sprays (e.g. obstructive airways diseases), eye drops or local injections (e.g. intra-articular) are allowed. Patients who are on a stable low dose corticosteroids treatment (e.g. dexamethasone 2 mg/day, prednisolone 10 mg/day) for at least 14 days before start of study treatment are eligible.
  • Ongoing ocular inflammation or infection.
  • Patients with significant (> grade 2) symptomatic ophthalmologic abnormalities such as:

    • Severe dry eye syndrome
    • Keratoconjunctivitis sicca
  • Patients with known HIV (testing not mandatory) infection.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT01591421
Other Study ID Numbers  ICMJE I208
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Current Responsible Party Canadian Cancer Trials Group
Original Responsible Party NCIC Clinical Trials Group
Current Study Sponsor  ICMJE Canadian Cancer Trials Group
Original Study Sponsor  ICMJE NCIC Clinical Trials Group
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Study Chair: Derek Jonker Ottawa Health Research Institute - General Division
PRS Account Canadian Cancer Trials Group
Verification Date April 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP